NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
+8.89%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$115M
AUM Growth
+$115M
(+21%)
Cap. Flow
+$20M
Cap. Flow
% of AUM
17.36%
Top 10 Holdings %
Top 10 Hldgs %
77.08%
Holding
49
New
17
Increased
12
Reduced
3
Closed
12
Top Buys
| 1 |
GSK
GSK
|
$20.4M |
| 2 |
Pfizer
PFE
|
$6.71M |
| 3 |
Amgen
AMGN
|
$4.57M |
| 4 |
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
|
$3.53M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$3.36M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$13.5M |
| 2 |
AGN
Allergan plc
AGN
|
$7.37M |
| 3 |
Bristol-Myers Squibb
BMY
|
$6.45M |
| 4 |
Sanofi
SNY
|
$4.7M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$3.65M |
Sector Composition
| 1 | Healthcare | 89.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$141B
| $22.1M | 19.1% | 626,438 +190,438 | +44% | +$6.71M |
|
|
2
GSK
GSK
$79.9B
| $20.4M | 17.64% | +470,000 | New | +$20.4M |
|
|
SHPG
3
DELISTED
Shire pic
SHPG
| $13.6M | 11.8% | 74,000 -2,200 | -3% | -$405K |
|
|
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.12M | 5.3% | 151,500 +48,500 | +47% | +$1.96M |
|
5
Viatris
VTRS
$12.3B
| $6.05M | 5.24% | 140,000 +4,000 | +3% | +$173K |
|
|
LCI
6
DELISTED
Lannett Company, Inc.
LCI
| $5.47M | 4.74% | 230,000 +80,000 | +53% | +$1.9M |
|
|
7
Amgen
AMGN
$155B
| $4.57M | 3.95% | +30,000 | New | +$4.57M |
|
|
CYNA
8
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
| $4.09M | 3.54% | 244,310 +210,594 | +625% | +$3.53M |
|
|
XLRN
9
DELISTED
Acceleron Pharma Inc.
XLRN
| $3.36M | 2.91% | +99,000 | New | +$3.36M |
|
10
Neurogene
NGNE
$264M
| $3.3M | 2.86% | +498,300 | New | +$3.3M |
|
|
ADMS
11
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $2.7M | 2.34% | 178,240 +61,240 | +52% | +$927K |
|
12
FibroGen
FGEN
$47.8M
| $2.53M | 2.19% | +154,000 | New | +$2.53M |
|
|
CNCE
13
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $2.06M | 1.78% | 183,000 | – | – |
|
|
AERI
14
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $1.94M | 1.68% | 110,280 +50,000 | +83% | +$880K |
|
|
ARRY
15
DELISTED
Array Biopharma Inc
ARRY
| $1.86M | 1.61% | +521,000 | New | +$1.86M |
|
16
Insmed
INSM
$28.8B
| $1.66M | 1.44% | 168,700 +128,700 | +322% | +$1.27M |
|
17
PDS Biotechnology
PDSB
$57.8M
| $1.37M | 1.19% | +135,836 | New | +$1.37M |
|
|
RXDX
18
DELISTED
Ignyta, Inc.
RXDX
| $1.27M | 1.1% | 235,000 +85,000 | +57% | +$461K |
|
19
Minerva Neurosciences
NERV
$16.5M
| $1.09M | 0.95% | 107,000 +72,900 | +214% | +$744K |
|
|
ADXS
20
DELISTED
Advaxis, Inc.
ADXS
| $1.01M | 0.88% | 125,000 +25,000 | +25% | +$202K |
|
|
ALDR
21
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $974K | 0.84% | +39,000 | New | +$974K |
|
|
TRVN
22
DELISTED
Trevena, Inc.
TRVN
| $945K | 0.82% | +150,000 | New | +$945K |
|
|
TBRA
23
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $942K | 0.82% | 75,000 +30,000 | +67% | +$377K |
|
|
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $922K | 0.8% | +145,250 | New | +$922K |
|
|
IMDZ
25
DELISTED
Immune Design Corp.
IMDZ
| $695K | 0.6% | 85,138 | – | – |
|